1. Frye MA, Nemeroff CB. Pharmacogenomic testing for antidepressant treatment selection: lessons learned and roadmap forward. Neuropsychopharmacology. 2023. https://doi.org/10.1038/s41386-023-01667-4.
2. Hicks JK, Bishop JR, Sangkuhl K, Muller DJ, Ji Y, Leckband SG, et al. Clinical pharmacogenetics implementation consortium (CPIC) guidelines for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors. CPT. 2015;98:127–34.
3. Bousman CA, Stevenson JM, Ramsey LB, Sangkuhl K, Hicks JK, Strawn JR, et al. Clinical pharmacogenetics implementation consortium (CPIC) guidelines for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A genotypes and serotonin reuptake inhibitor antidepressants. CPT. 2023;114:51–68.
4. Gold SM, Kohler-Forsberg O, Moss-Morris R, Mehnert A, Miranda JJ, Bullinger M, et al. Comorbid depression in medical diseases. Nat Rev Dis Primers. 2020;6: https://doi.org/10.1038/s41572-020-0200-2.
5. Loftus J, Levy HP, Stevenson JM. Documentation of results and medication prescribing after combinatorial psychiatric pharmacogenetic testing: a case for discrete results. Genet Med. 2023;26:101056.